Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju-si, South Korea.
Blood Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju-si, South Korea; Department of Life Science, University of Seoul, Seoul, South Korea.
Biologicals. 2023 May;82:101679. doi: 10.1016/j.biologicals.2023.101679. Epub 2023 May 3.
This study aimed to establish a second national standard for hepatitis B immunoglobulin (HBIG) that can be used for potency assays of hepatitis B and normal immunoglobulin. The candidate material was manufactured using a process approved as Good Manufacturing Practice. The freeze-dried candidate preparation was tested for physicochemical and biological properties, including pH, residual moisture, molecular size distribution, and potency. A collaborative study was performed involving four laboratories, including the National Institute of Food and Drug Safety Evaluation, as an official national control laboratory in Korea and manufacturers. The potency was calibrated against the second international standard for HBIG using two enzyme immunoassays: enzyme-linked immunosorbent assay and electrochemiluminescence immunoassay. Results from 240 assays were obtained from four laboratories, and combined potency estimates were obtained by calculating the geometric means. Intra- and inter-laboratory variability showed acceptable geometric coefficients of variation of 1.3-6.0 and 3.2-3.6%, respectively. The candidate preparation showed satisfactory stability in accelerated thermal degradation and real-time stability tests. Based on these results, the potency value of 105 IU/vial was assigned (95% confidence intervals: 100.0-109.2 IU/vial), and it was deemed suitable to serve as the Korean national standard for HBIG.
本研究旨在建立乙型肝炎免疫球蛋白(HBIG)的第二个国家标准,该标准可用于乙型肝炎和正常免疫球蛋白的效力测定。候选材料是按照良好生产规范(GMP)批准的工艺生产的。冻干候选制剂经过理化和生物学特性测试,包括 pH 值、残余水分、分子大小分布和效力。该研究涉及四个实验室,包括韩国国家食品和药物安全评估研究所(作为官方国家对照实验室)和制造商,进行了合作研究。使用两种酶联免疫吸附测定法(酶联免疫吸附测定法和电化学发光免疫测定法),用第二个乙型肝炎国际标准品对效力进行校准。从四个实验室获得了 240 次检测的结果,并通过计算几何平均值获得了合并的效力估计值。实验室内部和实验室之间的变异性分别显示出可接受的几何变异系数为 1.3-6.0 和 3.2-3.6%。候选制剂在加速热降解和实时稳定性测试中表现出令人满意的稳定性。基于这些结果,赋予了 105 IU/小瓶的效力值(95%置信区间:100.0-109.2 IU/小瓶),并认为其适合作为韩国 HBIG 的国家标准。